Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Jan 24;2007(1):CD004996.
doi: 10.1002/14651858.CD004996.pub3.

Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis

F Lirussi  1 , L Azzalini, S Orando, R Orlando, F Angelico
Affiliations
Meta-Analysis

Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis

F Lirussi et al. Cochrane Database Syst Rev. .

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is characterised by fatty deposition in the hepatocytes of patients with minimal or no alcohol intake and without other known cause. NAFLD includes a wide spectrum of histologic abnormalities ranging from hepatic steatosis to non-alcoholic steatohepatitis (NASH), or even cirrhosis. Antioxidant supplements, therefore, could potentially protect cellular structures against oxidative stress and the resulting lipid peroxidation.

Objectives: To systematically evaluate the beneficial and harmful effects of antioxidant supplements versus no intervention, placebo, or other interventions for patients with NAFLD or NASH.

Search strategy: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (June 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2006), MEDLINE (1966 to June 2006), EMBASE (1980 to June 2006), and the Chinese Biomedical Database (1978 to June 2006). No language restrictions were applied.

Selection criteria: Randomised clinical trials evaluating any antioxidant supplements versus no intervention, placebo, or other interventions in patients with NAFLD or NASH. Our inclusion criteria for NAFLD or NASH were based on history of minimal or no alcohol intake, imaging techniques showing hepatic steatosis, and/or histological evidence of hepatic damage (including simple steatosis, fatty infiltration plus nonspecific inflammation, steatohepatitis, fibrosis, and cirrhosis), and by exclusion of other causes of hepatic steatosis.

Data collection and analysis: We extracted data from the identified trials and contacted authors. We used a random-effects model and fixed-effect model with the significant level set at P = 0.05. We evaluated the methodological quality of the randomised trials by looking at how the generation of allocation sequence, allocation concealment, blinding, and follow-up were performed. We made our analyses following the intention-to-treat method by imputing missing data.

Main results: We identified six trials: two were regarded of high methodological quality and four of low methodological quality. None of the trials reported any deaths. Treatment with antioxidant supplements showed a significant, though not clinically relevant, amelioration of aspartate aminotransferase levels, but not of alanine aminotransferase levels, as compared to placebo or other interventions. Gamma-glutamyl-transpeptidase was decreased, albeit not significantly, in the treatment arm. Radiological and histological data were too limited to draw any definite conclusions on the effectiveness of these agents. Adverse events were non-specific and of no major clinical relevance.

Authors' conclusions: There is insufficient data to either support or refute the use of antioxidant supplements for patients with NAFLD. It may be advisable to carry out large prospective randomised clinical trials on this topic.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Mortality, Outcome 1 All cause mortality.
2.1
2.1. Analysis
Comparison 2 Radiological response, Outcome 1 US pattern improvement.
2.2
2.2. Analysis
Comparison 2 Radiological response, Outcome 2 US bright liver persistence.
3.1
3.1. Analysis
Comparison 3 Biochemical response, Outcome 1 Aspartate aminotransferase activity (IU/L).
3.2
3.2. Analysis
Comparison 3 Biochemical response, Outcome 2 Alanine aminotransferase activity (IU/L)).
3.3
3.3. Analysis
Comparison 3 Biochemical response, Outcome 3 Alanine aminotransferase activity (Vitamin E vs other antioxidants) (IU/L).
3.4
3.4. Analysis
Comparison 3 Biochemical response, Outcome 4 Gamma‐glutamyl‐transpeptidase activity (IU/L).
3.5
3.5. Analysis
Comparison 3 Biochemical response, Outcome 5 Serum total bilirubin levels (umol/L).
4.1
4.1. Analysis
Comparison 4 Histological response, Outcome 1 Fibrosis persistence.
4.2
4.2. Analysis
Comparison 4 Histological response, Outcome 2 Fibrosis improvement.
4.3
4.3. Analysis
Comparison 4 Histological response, Outcome 3 Necro‐inflammatory improvement.
5.1
5.1. Analysis
Comparison 5 Adverse events, Outcome 1 Headache.
5.2
5.2. Analysis
Comparison 5 Adverse events, Outcome 2 Nausea.
5.3
5.3. Analysis
Comparison 5 Adverse events, Outcome 3 Diarrhea.
5.4
5.4. Analysis
Comparison 5 Adverse events, Outcome 4 Heartburn.
5.5
5.5. Analysis
Comparison 5 Adverse events, Outcome 5 Meteorism.
5.6
5.6. Analysis
Comparison 5 Adverse events, Outcome 6 Increase of transaminase.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD004996.pub2

References

References to studies included in this review

Bugianesi 2005 {published data only}
    1. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus Vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology 2005;100:1082‐90. - PubMed
Harrison 2003 {published data only}
    1. Harrison S, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology 2003;98:2485‐90. - PubMed
Miglio 2000 {published data only}
    1. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non‐alcoholic steatohepatitis. Leber‐Therapeutika 2000;50(2):722‐7. - PubMed
Pamuk 2003 {published data only}
    1. Pamuk GE, Sonsuz A. N‐acetylcysteine in the treatment of non‐alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2003;18(10):1220‐1. - PubMed
Rui 2001 {published data only}
    1. Rui M, Wang C, Fang J, et al. The clinical comparison of reduced glutathione and DanNingPlan in the treatment of nonalcoholic steatohepatitis. Chinese General Practice 2001;4(4):269‐70.
Vajro 2004 {published data only}
    1. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello, Savoia M, et al. Vitamin E treatment in pediatric obesity‐related liver disease: a randomized study. Journal of Pediatric Gastroenterology 2004;38:48‐55. - PubMed

References to studies excluded from this review

Abdelmalek 2001 {published data only}
    1. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. The American Journal of Gastroenterology 2001;96(9):2711‐7. - PubMed
Dentico 1995 {published data only}
    1. Dentico P, Volpe A, Buongiorno R, Grattagliano I, Altomare E, Tantimonaco G, et al. Glutathione in the treatment of chronic fatty liver diseases [Il glutatione nella terapia dell'epatopatie croniche steatosiche]. Recenti Progressi in Medicina 1995;86(7‐8):290‐3. - PubMed
Hasegawa 2001 {published data only}
    1. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor‐beta1 level and efficacy of alpha‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study. Alimentary Pharmacology & Therapeutics 2001;15(10):1667‐72. - PubMed
Kugelmas 2003 {published data only}
    1. Kugelmas M, Hill D, Vivian B, Marsano L, McClain C. Cytokines and NASH: a pilot study of the effect of lifestyle modification and vitamin E. Liver Failure and Liver Disease 2003;38(2):413‐9. - PubMed
Lavine 2000 {published data only}
    1. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. The Journal of Pediatrics 2000;136(6):734‐42. - PubMed
Lu 2005 {published data only}
    1. Lu L, Zeng M, Mao Y, Chen C, Fu Q, Wang J. Diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver disease: a multicenter random double‐blind controlled trial. Chinese Journal of Hepatology 2005;13(2):92‐5. - PubMed
Merat 2003 {published data only}
    1. Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, et al. Probucol in the treatment of nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2003;36(3):266‐8. - PubMed
Sanyal 2004 {published data only}
    1. Sanyal A, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology 2004;2:1107‐15. - PubMed
Trappoliere 2005 {published data only}
    1. Trappoliere M, Federico A, Tuccillo C, Sio I, leva A, Niosi M, et al. Effects of new pharmacological complex (sylibin+vitamin E+phospolipids) on some markers of metabolic syndrome and of a liver fibrosis in patients with non‐alcoholic fatty liver disease: a preliminary open pilot study. Minerva Gastroenterologica e Dietologica 2005;51:193‐9. - PubMed

References to ongoing studies

Dufour 2005 {published data only}
    1. Dufour JF, Oneta C, Gonvers JJ, Bihl F, Cerny A, Cereda JM. A 2‐years multicenter randomized placebo‐controlled study testing UDCA in combination with vitamin E to treat NASH. Journal of Hepatology 2005;12(Supplement 2):4‐5.

Additional references

Angelico 2007
    1. Angelico F, Burattin M, Alessandri C, Ben M, Lirussi F. Drugs improving insulin resistance for non‐alcoholic fatty liver disease and/or non‐alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005166. DOI: 10.1002/14651858.CD005166.pub2. - PubMed
Angulo 2002a
    1. Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine 2002;16:1221‐31. - PubMed
Angulo 2002b
    1. Angulo P, Lindor KD. Treatment of non‐alcoholic steatohepatitis. Best Practice & Research. Clinical Gastroenterology 2002;16(5):797‐810. - PubMed
Bacon 1994
    1. Bacon BR, Farahvash MJ, Janney CG, Neuschwander‐Tetri BA. Non‐alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103‐9. - PubMed
Becker 1996
    1. Becker U, Deis A, Sorensen TI, Gronbæk M, Borch‐Johnsen K, Florvall Muller C, et al. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996;23(5):1025‐9. - PubMed
Brolin 1998
    1. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during obesity operations. Archives of Surgery 1998;133:84‐8. - PubMed
Brunt 1999
    1. Brunt EM, Janney CG, Bisceglie AM, Neuschwander‐Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999;94(9):2467‐74. - PubMed
Caldwell 1999
    1. Calwell SH, Oelsner DH, Iezzoni J, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664‐9. - PubMed
Chitturi 2001
    1. Chitturi S, Farrell GC. Etiopathogenesis of non‐alcoholic steatohepatitis. Seminars in Liver Diseases 2001;21:27‐41. - PubMed
Chitturi 2002a
    1. Chitturi S, Abeygunasekera S, Farrell GC, Holmes‐Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373‐9. - PubMed
Clark 2006
    1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. Journal of Clinical Gastroenterology 2006;40(3 Suppl 1):S5‐S10. - PubMed
DeMets 1987
    1. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. [MEDLINE: ] - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed
Farrell 2003
    1. Farrell GC. Non‐alcoholic steatohepatitis: what is it, and why is it important in the Asia‐Pacific region?. Journal of Gastroenterology and Hepatology 2003;18:124‐38. - PubMed
Farrell 2006
    1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(2 Suppl 1):S99‐S112. - PubMed
Gluud 2006
    1. Gluud C, Als‐Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al. Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER.
Higgins 2006
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & sons, Ltd.
Jimba 2005
    1. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Medicine 2005;22(9):1141‐5. - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. [MEDLINE: ] - PubMed
Kleiner 2005
    1. Kleiner DE, Brunt EM, Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313‐21. - PubMed
Liou 2006
    1. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2006;40(3 Suppl 1):S11‐S16. - PubMed
McCullough 2002
    1. McCullough AJ. Update on nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology 2002;34(3):255‐62. - PubMed
Miller 2005
    1. Miller ER 3rd, Pastor‐Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta‐analysis: high‐dosage vitamin E supplementation may increase all‐cause mortality. Annals of Internal Medicine 2005;142(1):37‐46. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. [MEDLINE: ] - PubMed
Neuschwander‐T 2003
    1. Neuschwander‐Tetri BA, Caldwell ST. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37(5):1202‐19. - PubMed
Poonawala 2000
    1. Poonawala A, Nair S, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case‐control study. Hepatology 2000;32:689‐92. - PubMed
RevMan 2003 [Computer program]
    1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [MEDLINE: ] - PubMed
Wang 2002
    1. Wang RT, Koretz RL, Yee HF. Weight reduction for non‐alcoholic fatty liver. (Protocol) The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003619. DOI: 10.1002/14651858.CD003619. - PubMed
Younossi 2002
    1. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35(4):746‐52. - PubMed